Evidence map›Paper›PMID 31396278›Full record

ArticleJournal of oncology2019

HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia.

Aida Vitkevičienė, Giedrė Skiauterytė, Andrius Žučenka, Mindaugas Stoškus, Eglė Gineikienė, Veronika Borutinskaitė, Laimonas Griškevičius, Rūta Navakauskienė

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Aida VitkevičienėDepartment of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-01257 Vilnius, Lithuania.ORCID https://orcid.org/0000-0002-9347-5333
Giedrė SkiauterytėDepartment of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-01257 Vilnius, Lithuania.
Andrius ŽučenkaHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu Str. 2, LT-08661 Vilnius, Lithuania.
Mindaugas StoškusHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu Str. 2, LT-08661 Vilnius, Lithuania.
Eglė GineikienėHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu Str. 2, LT-08661 Vilnius, Lithuania.
Veronika BorutinskaitėDepartment of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-01257 Vilnius, Lithuania.ORCID https://orcid.org/0000-0001-6077-0136
Laimonas GriškevičiusHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu Str. 2, LT-08661 Vilnius, Lithuania.
Rūta NavakauskienėHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu Str. 2, LT-08661 Vilnius, Lithuania.ORCID https://orcid.org/0000-0002-1077-9439
Vilnius University Hospital Santariskiu Klinikos · LTVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is characterized by

Identifiers

PMID31396278
PMCPMC6668531
OpenAlexW2956279815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.